Skip to main content

China s Shanghai Genomics Merges with Japan s GNI; Combined Firm Raises $13M

NEW YORK, June 20 (GenomeWeb News) - Japan's Gene Networks International (GNI) said today that it has merged with China's Shanghai Genomics.


GNI said that it concurrently raised a private equity round of financing of more than $13M led by Nomura, Healthcare Partners, and several other US and Japanese private equity firms.


GNI uses gene regulatory network maps and systems pharmacology techniques to develop therapeutic pharmaceutical products internally and in partnerships with other pharmaceutical firms. The company, which has offices in Japan, the UK, and the US, said that it will benefit from Shanghai Genomics' "Western-quality discovery research, preclinical development, and contract research services to facilitate cost-efficient drug development, faster revenue generation and, ultimately, profitability for the united company."


The combined company will have a research staff of more than 80 employees in Japan, China, and the UK, and several drug candidates in clinical and pre-clinical development, GNI said.

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.